07.07.2021 - Taking the next step towards medical breakthroughs: Viscofan BioEngineering has submitted Master File documentation (MAF) for medical grade Viscolma® collagen suspension to the U.S. Food and Drug Administration (FDA). This technical documentation facilitates FDA-compliant developments of U.S.-collaborators that use Viscolma® in regenerative medicine, tissue engineering, medical device technology, implantology, ATMPs, or as bioinks in 3D bioprinting.
Read press release
08.06.2021 - As coordinator of the project for the development of a regenerative therapy for ankle injuries, Viscofan BioEngineering has launched the TriAnkle website.
It will serve as a universal platform that provides information on background and progress of the TriAnkle project – a joint research endeavor of 12 partners from 5 European countries to develop innovative personalized collagen- and gelatine-based implants manufactured with 3D technology for patients suffering from osteoarticular diseases. The project is funded by the European Commission with €5.9 Million as part of the Horizon 2020 program.
Visit the TriAnkle website!
20.01.2021 – The certified quality system for medical device manufacturing ensures safe applications of our cell-carrying collagen membranes and coated implants in tissue engineering and regenerative medicine.
Read press release
23.11.2020 – Viscofan BioEngineering is part of a new international consortium led by Pfizer and the University of Sheffield aiming to standardize and accelerate the development of Advanced Therapy Medicinal Products (ATMPs).
Read press release
09.11.2020 – The TRIANKLE project, consisting of a research consortium of 12 partners from 5 European countries has been granted today by the European Commission as part of the Horizon 2020 program. Viscofan BioEngineering will function as coordinator of the ambitious project for the development and production of personalized bio-implants for injured tendons and cartilages.
Read the press release (English)
Read the press release (German)
23.03.2020 – Our operations are continuing with protective measures for our employees against SARS-CoV-2 and all products can be ordered as usual. Furthermore, to support R&D for effective COVID-19 vaccines or treatments, we offer our collagen products free of charge for coronavirus projects.
Download our coronavirus statement
Viscofan S. A., the parent company of Viscofan BioEngineering has acquired the casing collagen division from the Japanese Group Nitta Gelatin Inc. that is specialized in the production and distribution of collagen products for pharmaceutical, food and industrial markets.
This new addition to the Viscofan group provides a significant opportunity for Viscofan BioEngineering to access new market segments for its biomedical collagen products, especially in the USA.
Read Viscofan’s press release
Explore why we specialize in preserving the native, complex structure of collagen type I.
Read more about the yielded viscous mass of highly biocompatible and strong fibers to build up unique scaffolds, e.g. tear-resistant collagen membranes for tissue engineering and implantation, biocompatible coating of medical devices, customized scaffolds etc.
Learn about the preclinical success of our suturable Collagen Cell Carrier® membrane used to transfer and fix implanted stem cells to infarcted heart tissue to enhance their efficacy.
Download Technical Note
From now on, our collagen products for research & development can also be found on www.SelectScience.net and www.biocompare.com
Explore reviews of other scientists or write your own judgement about the Collagen Cell Carrier®, our soluble collagen type I, etc.
Viscofan BioEngineering advances collagenous carrier material as their first medical product to clinical development.
Download press release
As part of its business development strategy, Viscofan BioEngineering pursues sustainable investments in biomedical research collaborations with public centers. According to the transparency rules established by EFPIA for the biopharmaceutic industry, Viscofan BioEngineering discloses annually the R&D expenses performed with public centers.
In 2017, Viscofan BioEngineering spent 88.000 € for the development of its product pipeline in regenerative medicine in joint projects with university and clinics which was backed by an additional 138.000€ in public funding.
Within the framework of the BioRN Annual Conference 2017: “Revolution through convolution – combining medtech, biotech and digital health to promote health science in our region”, corporate manager Dr. Lluís Quintana gave a talk entitled: „Viscofan BioEngineering – von der Wursthülle zum Medizinprodukt – from sausage casing to medical device“.
Viscofan BioEngineering celebrates new GMP-facility with opening ceremony